Latest news with #NGS
Yahoo
6 minutes ago
- Business
- Yahoo
Natural Gas Services Group, Inc. Initiates First Quarterly Dividend
Announces 2025 Second Quarter Earnings Release and Conference Call Schedule Midland, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (NYSE: NGS), ('NGS' or the 'Company'), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that its Board of Directors has declared the first-ever quarterly cash dividend of $0.10 per share of common stock, or $0.40 per share of common stock on an annualized basis. This cash dividend will be paid on August 22, 2025 to all stockholders of record as of the close of business on August 8, 2025. Justin Jacobs, Chief Executive Officer of NGS stated, 'This dividend marks a significant milestone in the history of NGS. It is a testament to our strong financial performance, confidence in the future of our business, and commitment to delivering long-term shareholder value. We believe now is an ideal time to initiate a modest dividend as our business continues to grow and take market share, and our balance sheet and low leverage ratio have us in perhaps the best financial position in the industry. The initial dividend represents the beginning of our shareholder return of capital plan—we expect this plan to grow as our business continues to expand faster than our competition.' Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. NGS also announced today that it will release its second quarter 2025 financial results on Monday, August 11, 2025, after the market closes via press release and made available on the Company's website ( Management will host a conference call to review the results and provide an update on business operations at 8:30 a.m. (EDT), 7:30 a.m. (CDT) on Tuesday, August 12, 2025. To join the conference call, kindly access the Investor Relations section of our website ( or dial in at (800) 550-9745 and enter conference ID: 167298 at least five minutes prior to the scheduled start time. Please note that using the provided dial-in number is necessary for participation in the Q&A section of the call. A recording of the conference will be made available on our Company's website following its conclusion. Thank you for your interest in our company's updates. Forward-Looking StatementsCertain statements in this release regarding future cash dividends may be 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Future dividends or dividends at any particular rate is subject to the discretion of the Board of Directors and will depend on our financial condition, results of operations, capital requirements, business conditions and other factors, as well as a determination by the Board of Directors that dividends are in the best interests of our shareholders. About Natural Gas Services Group, Gas Services Group is a leading provider of natural gas compression equipment, technology and services to the energy industry. The Company designs, rents, sells and maintains natural gas compressors for oil and natural gas production and plant facilities, primarily using equipment from third-party fabricators and OEM suppliers along with limited in-house assembly. The Company is headquartered in Midland, Texas, with a fabrication facility located in Tulsa, Oklahoma, and service facilities located in major oil and natural gas producing basins in the U.S. Additional information can be found at For Additional Information:Anna Delgado – Investor Relations(432) 262-2700ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Business
- Yahoo
Paragon Genomics and Genecast Announce Global Partnership to Advance Precision Oncology
Leaders in pioneering cancer diagnostics and NGS target enrichment technologies join forces to accelerate access to advanced molecular diagnostics for cancer FREMONT, Calif. and TAIZHOU, China, July 30, 2025 (GLOBE NEWSWIRE) -- Paragon Genomics, Inc., a global leader in target enrichment solutions for next-generation sequencing (NGS), and Genecast (Taizhou) Biotechnology Co., Ltd., a pioneering oncology diagnostics company, today announced a strategic global partnership to accelerate access to cutting-edge molecular diagnostic technologies for cancer care worldwide. This collaboration brings together Paragon Genomics' high-performance CleanPlex® NGS technologies with Genecast's deep expertise in oncology assay development and clinical deployment. The partnership aims to deliver comprehensive, scalable precision oncology solutions to researchers, clinicians, and diagnostic labs across international markets. 'This partnership is perfectly aligned with our mission to facilitate the widespread availability of advanced genomic technologies, and we are delighted to join forces with Genecast to drive innovation in cancer diagnostics on a global scale,' said Tao Chen, CEO of Paragon Genomics. 'Our leading NGS target enrichment technologies are a strong complement to Genecast's comprehensive and innovative oncology platforms, and together we're poised to expand access to accurate, efficient, and accessible diagnostic tools that can transform patient outcomes.' 'This partnership reflects our mutual commitment to advancing precision medicine for cancer,' said Dr. Bo Du, CEO of Genecast. 'By integrating Paragon's world-class target enrichment technologies into our molecular diagnostics workflow, we can offer higher sensitivity, greater reliability, and broader reach to cancer care providers globally.' The collaboration will initially focus on supporting the Genecast Focus Assay, a multiplex PCR-based sequencing panel used to evaluate key somatic variants and microsatellite instability (MSI) in solid tumors, including lung and colorectal cancers. The test is already deployed in hospitals and reference labs across multiple regions and is certified under CE-IVD for clinical use. Incorporating the CleanPlex technology will further enhance the sensitivity and reliability of this important diagnostic tool. Importantly, both companies plan to expand the partnership beyond the Genecast Focus Assay. Future collaborations will include the co-development and global deployment of additional oncology panels and advanced molecular tests, further strengthening their shared commitment to innovation in precision medicine. This global partnership underscores both companies' dedication to empowering precision oncology through scientific innovation, operational excellence, and a shared mission to improve outcomes for cancer patients worldwide. About Paragon GenomicsParagon Genomics ( is a leading developer of amplicon-based target enrichment and NGS library preparation technologies that accelerate the advancement of next-generation sequencing (NGS) assays for research and clinical applications. The company designs and manufactures high-performance, ultra-multiplexed amplicon NGS kits optimized for challenging and clinically relevant samples. Its CleanPlex® technology is trusted globally for high-performance sequencing in clinical and translational research across oncology, infectious diseases, hereditary disorders, and more. CleanPlex® is an ultra-scalable and ultra-sensitive NGS target enrichment technology that provides single cell level direct amplification sensitivity and makes it possible to include a large number of genomic targets in a single assay. It features a highly advanced proprietary multiplex PCR primer design algorithm, an exceptionally uniform multiplex PCR amplification chemistry and an innovative, patented background cleaning chemistry. The CleanPlex technology's very high amplification uniformity and low PCR background noise deliver more accurate variant calling and lower sequencing costs. The assay is compatible with difficult samples and major sequencing platforms. Paragon Genomics serves as a trusted partner to research institutions, clinical laboratories, and diagnostic developers worldwide, making high-quality custom NGS panels accessible to a broad range of users. The company is privately held and headquartered in Fremont, California. About GenecastGenecast ( is a leading precision oncology diagnostics company based in China, specializing in the development and clinical implementation of molecular assays across the full cancer care continuum, including early detection, therapy selection, prognosis, and recurrence monitoring. The company's test portfolio integrates multiplex PCR and hybrid-capture-based targeted NGS to profile cancer mutations from both tissue DNA and RNA, as well as liquid biopsy samples. Leveraging high-throughput sequencing, proprietary bioinformatics, and translational research, Genecast offers precision oncology solutions covering over 20+ cancer types. Genecast delivers diagnostic insights to hospitals, clinical labs, and research partners worldwide, supporting personalized cancer care. The company leads China in multi-omics oncology testing and holds certifications under CAP, ISO, CE-IVD, and NMPA. Contacts: Paragon Genomics Corporate:Shane WeckhurstMarket Development Managerinfo@ Paragon Genomics Media:Barbara LindheimBLL Partners for Paragon Genomicsblindheim@ (917) 355-9234 Genecast Corporate:Casey ZhengDirector/Global Business Media:Dan ChenPR
Barnama
11 hours ago
- Health
- Barnama
Lung Cancer Survival Doubles With Advances In Modern Therapies, Says Expert
Clinical Oncologist Dr. David Lee during an exclusive interview in conjunction with World Lung Cancer Day at Sunway Medical Centre, Sunway City. KUALA LUMPUR, July 30 (Bernama) -- Lung cancer, long known as a 'silent killer' and consistently among the top three causes of cancer-related deaths in Malaysia, is now seeing a shift in outlook. Clinical Oncologist at Sunway Medical Centre, Sunway City (SMC), Dr David Lee Dai Wee said, thanks to advances in modern therapies, patient survival rates are doubling, offering new hope where it was once scarce. He highlighted that nearly 60 percent of lung cancer patients in Malaysia are only diagnosed at stage four, the most advanced stage, with a five-year survival rate of less than 15 percent, according to the National Cancer Registry. 'In the early stages, such as stage one or two, patients often experience no symptoms at all. As a result, lung cancer is frequently diagnosed at a later stage when symptoms begin to appear. These may include a persistent cough lasting two to three weeks or longer,' he told Bernama. Other symptoms may include coughing up blood (hemoptysis), chest pain during breathing, shortness of breath and unexplained weight loss, said Dr Lee, adding that the spread of cancer to other organs may also cause pain in different parts of the body. He noted that while tobacco smoking is responsible for around 80 percent of lung cancer cases, exposure to secondhand smoke, hazardous substances such as asbestos and coal, as well as genetic predisposition, also contribute significantly to the disease's risk profile. Dr Lee also highlighted that 20 to 30 percent of lung cancer patients in Asia are non-smokers, challenging the common misconception that only smokers are affected, a belief that may lead patients or primary care doctors to delay further testing to determine whether symptoms are related to lung cancer. 'But now, due to advances, firstly in molecular pathology, we are able to run this test called Next Generation Sequencing (NGS), which allows us to read the DNA (deoxyribonucleic acid) of the cancer cells and understand them better. 'And this has significantly improved treatment for this type of cancer. So, for example, let's say in a hundred patients of lung cancer that I see, about 50 percent have this genetic change called Epidermal Growth Factor Receptor (EGFR) mutation,' he said.
Business Wire
a day ago
- Business
- Business Wire
NeoGenomics Reports Second Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO) (the ' Company '), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025. 'In the second quarter clinical revenue increased by 16% driven by sequential improvement in AUP, a record quarter for volumes, and NGS growth of 23%,' said Tony Zook, CEO of NeoGenomics. 'Strength in our Clinical business was largely offset by continuing pressure in pharma revenue that was beyond our initial assumptions, and a delay in our commercial launch of PanTracer™ Liquid Biopsy that impacted our expected NGS revenue.' 'Looking ahead, we believe Neo will continue to perform as a double-digit revenue growth company, poised to capture additional market share,' continued Mr. Zook. 'We are enhancing our R&D efforts to develop new therapy selection and next-gen MRD products. We are also preparing for the commercial launch of PanTracer Liquid Biopsy, continuing to grow our sales team, increasing efficiencies, and pursuing partnerships through business development efforts that will enhance our portfolio and strengthen our community channel. We are confident that Neo will deliver long-term value for our customers, patients, and shareholders.' Second-Quarter Results Consolidated revenue for the second quarter of 2025 was $181 million, an increase of 10% over the same period in 2024 primarily due to higher volume partially offset by lower non-clinical revenue. Average revenue per clinical test ('revenue per test') increased by 2% to $465. This increase reflects higher value tests, including NGS, and strategic reimbursement initiatives. Consolidated gross profit for the second quarter of 2025 was $77 million, an increase of 7% compared to the second quarter of 2024. This increase was primarily due to an increase in revenue partially offset by higher compensation and benefit costs and an increase in supplies expense. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based compensation expense, was 43%. Adjusted Gross Profit Margin (1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 45%. Operating expenses for the second quarter of 2025 were $125 million, an increase of $30 million, or 32%, compared to the second quarter of 2024. The increase in operating expenses primarily reflect $20.0 million of impairment charges from impairment of assets held for sale related to the planned sale of Trapelo and the InVisionFirst®-Lung intangible asset impairments, as well as $4.4 million in higher compensation and benefit costs. These increases were partially offset by a decrease in restructuring activities due to the completion of restructuring activities in the fourth quarter of 2024. Net loss for the quarter increased $26 million, or 142%, to $45 million compared to net loss of $19 million for the second quarter of 2024. Adjusted EBITDA (1) for the second quarter of 2025 remained relatively flat at positive $10.7 million, compared to positive $10.9 million in the second quarter of 2024. Adjusted Net Loss (1) was $3.6 million compared to Adjusted Net Loss (1) of $4 million in the second quarter of 2024. Cash and cash equivalents and marketable securities totaled $164 million at quarter end. Pathline, LLC Acquisition On April 4, 2025, the Company completed the acquisition of a 100% ownership interest in Pathline, LLC ('Pathline'), a CLIA/CAP/NYS-certified laboratory based in New Jersey. The purchase price consisted of (i) initial cash consideration of $8.0 million, subject to working capital and other adjustments, and (ii) contingent consideration of $1.0 million. The Pathline acquisition aligns with the Company's strategic objective of expanding its presence, capabilities, and offerings in the Northeastern United States. 2025 Financial Guidance (2) The Company again revised its full-year 2025 guidance (2), as previously revised on April 29, 2025. ____________________ Expand (1) The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled 'Use of Non-GAAP Financial Measures.' See also the tables reconciling such measures to their closest GAAP equivalent. (2) The Company reserves the right to adjust this guidance at any time. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities and are reminded that the foregoing estimates should not be construed as guarantees of future performance. Expand Conference Call The Company has scheduled a webcast and conference call to discuss its second quarter 2025 results on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 859170. The live webcast may be accessed by visiting the Investor Relations section of our website at A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. We routinely post information that may be important to investors on our website at Forward Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'plan,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding 2025 financial guidance, seasonality impacts, and long-range strategic objectives and initiatives set forth in the Company's long-range plans.. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to assemble and maintain an effective executive team, to continue gaining new customers, offer new types of tests, integrate its acquisitions, manage the effects of seasonality, execute on its long-range strategic priorities, and otherwise implement its business plans, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and filed with the SEC on February 18, 2025, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and on our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, COST OF REVENUE 104,072 92,008 198,861 182,779 GROSS PROFIT 77,258 72,494 150,504 137,963 Operating expenses: General and administrative 71,747 63,328 139,954 129,125 Research and development 9,023 7,886 19,204 15,506 Sales and marketing 24,075 21,677 46,758 41,898 Restructuring charges — 1,544 — 3,942 Impairment charges 20,041 — 20,041 — Total operating expenses 124,886 94,435 225,957 190,471 LOSS FROM OPERATIONS (47,628 ) (21,941 ) (75,453 ) (52,508 ) Interest income (2,263 ) (4,592 ) (5,984 ) (9,426 ) Interest expense 933 1,666 2,551 3,351 Other (income) expense, net (482 ) 2 (547 ) 265 Loss before taxes (45,816 ) (19,017 ) (71,473 ) (46,698 ) Income tax benefit (724 ) (375 ) (458 ) (995 ) NET LOSS $ (45,092 ) $ (18,642 ) $ (71,015 ) $ (45,703 ) NET LOSS PER SHARE Basic $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) Diluted $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) WEIGHTED AVERAGE COMMON SHARES OUTSTANDING Basic 127,949 126,405 127,664 126,257 Diluted 127,949 126,405 127,664 126,257 Expand NeoGenomics, Inc. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) Six Months Ended June 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (71,015 ) $ (45,703 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 18,506 19,651 Amortization of intangibles 16,486 16,723 Stock-based compensation 22,968 16,615 Non-cash operating lease expense 3,353 4,793 Amortization of convertible debt discount and debt issue costs 1,233 1,452 Impairment charges 20,041 — Other impairment charges — 333 Other adjustments (340 ) 159 Changes in assets and liabilities, net (16,229 ) (26,046 ) Net cash used in operating activities (4,997 ) (12,023 ) CASH FLOWS FROM INVESTING ACTIVITIES Proceeds from maturities of marketable securities 11,060 40,501 Purchases of property and equipment (10,823 ) (18,663 ) Business acquisition, net of cash acquired (5,991 ) — Net cash (used in) provided by investing activities (5,754 ) 21,838 CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock, net (234 ) 2,782 Repayment of convertible debt (201,250 ) — Net cash (used in) provided by financing activities (201,484 ) 2,782 Net change in cash and cash equivalents, including cash classified within current assets held for sale (212,235 ) 12,597 Less: net change in cash classified within current assets held for sale (54 ) — Net change in cash and cash equivalents (212,289 ) 12,597 Cash and cash equivalents, beginning of period 367,012 342,488 Cash and cash equivalents, end of period $ 154,723 $ 355,085 Expand Use of Non-GAAP Financial Measures In order to provide greater transparency regarding our operating performance, the financial results and financial guidance in this press release refer to certain non-GAAP financial measures that involve adjustments to GAAP results. Non-GAAP financial measures exclude certain income and/or expense items that management believes are not directly attributable to the Company's core operating results and/or certain items that are inconsistent in amounts and frequency, making it difficult to perform a meaningful evaluation of our current or past operating performance. Management believes that the presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors by facilitating the analysis of the Company's core test-level operating results across reporting periods. These non-GAAP financial measures may also assist investors in evaluating future prospects. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the business. These non-GAAP financial measures do not replace the presentation of financial information in accordance with U.S. GAAP financial results, should not be considered measures of liquidity, and are unlikely to be comparable to non-GAAP financial measures provided by other companies. Definitions of Non-GAAP Measures Non-GAAP Adjusted EBITDA 'Adjusted EBITDA' is defined by NeoGenomics as net (loss) income from continuing operations before: (i) interest income, (ii) interest expense, (iii) tax (benefit) or expense, (iv) depreciation and amortization expense, (v) stock-based compensation expense, and, if applicable in a reporting period, (vi) CEO transition costs, (vii) restructuring charges, (viii) impairment charges, (ix) intellectual property ('IP') litigation costs, and (x) other significant or non-operating (income) or expenses, net. Non-GAAP Adjusted Cost of Revenue, Adjusted Gross Profit and Adjusted Gross Profit Margin 'Adjusted cost of revenue' is defined by NeoGenomics as cost of revenue before: (i) amortization of acquired intangible assets, and, if applicable in a reporting period, (ii) stock-based compensation expense. 'Adjusted gross profit' is defined by NeoGenomics as total revenue less adjusted cost of revenue. 'Adjusted gross profit margin' is defined by NeoGenomics as adjusted cost of revenue divided by total revenue. Non-GAAP Adjusted Net (Loss) Income 'Adjusted net (loss) income' is defined by NeoGenomics as net (loss) income from continuing operations plus: (i) amortization of intangible assets, (ii) stock-based compensation expense, and, if applicable in a reporting period, (iii) CEO transition costs, (iv) restructuring charges, (v) impairment charges, (vi) IP litigation costs, and (vii) other significant or non-operating (income) or expenses, net. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method unless the effect of this adjustment on both the adjusted net (loss) income and weighted average diluted common shares outstanding would be anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted net (loss) income will also be adjusted to reverse any recognized interest expense (including any amortization of discounts) on the convertible notes using the if-converted method. Non-GAAP Adjusted Diluted EPS 'Adjusted diluted EPS' is defined by NeoGenomics as adjusted net (loss) income divided by adjusted diluted shares outstanding. If GAAP net (loss) income is negative and adjusted net (loss) income is positive, adjusted diluted shares outstanding will also include any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. If GAAP net (loss) income is positive and adjusted net (loss) income is negative, adjusted diluted shares outstanding will exclude any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period. ____________________ Expand (1) For the three months ended June 30, 2025, CEO transition costs include executive retention costs. For the six months ended June 30, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three and six months ended June 30, 2024. (2) For the three and six months ended June 30, 2025, acquisition and integration related expenses include consulting and legal fees, severance costs, and employee retention costs. (3) For the three and six months ended June 30, 2025, impairment charges include losses from InVisionFirst®-Lung intangible asset impairment and inventory write-off, and impairment of disposal groups held for sale. There were no such costs for the three and six months ended June 30, 2024. (4) For the three and six months ended June 30, 2025 and June 30, 2024, IP litigation costs include legal fees. (5) For the three and six months ended June 30, 2024, other significant (income) expenses, net, includes site closure costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three and six months ended June 30, 2025. Expand ____________________ Expand (1) Cost of revenue adjustments for the three months ended June 30, 2025, includes $4.8 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the six months ended June 30, 2025, includes $9.7 million of amortization of acquired intangible assets and $0.7 million of stock-based compensation. Cost of revenue adjustments for the three months ended June 30, 2024, includes $4.9 million of amortization of acquired intangible assets and $0.3 million of stock-based compensation. Cost of revenue adjustments for the six months ended June 30, 2024, includes $9.8 million of amortization of acquired intangible assets and $0.7 million of stock-based compensation. Expand Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and GAAP EPS to Non-GAAP Adjusted EPS (in thousands, except per share amounts) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss (GAAP) $ (45,092 ) $ (18,642 ) $ (71,015 ) $ (45,703 ) Adjustments to net loss, net of tax: Amortization of intangibles 8,124 8,361 16,486 16,723 CEO transition costs (1) 637 — 2,831 — Acquisition and integration related expenses (2) 3,204 — 4,376 — Stock-based compensation expense 12,215 8,841 22,968 16,615 Restructuring charges — 1,544 — 3,942 Impairment charges (2) 20,041 — 20,041 — IP litigation costs (3) 4,460 1,962 7,443 6,243 Other significant expenses, net (4) — 2,358 — 3,960 Adjusted net income $ 3,589 $ 4,424 $ 3,130 $ 1,780 Net loss per common share (GAAP) Diluted EPS $ (0.35 ) $ (0.15 ) $ (0.56 ) $ (0.36 ) Adjustments to diluted loss income per share: Amortization of intangibles 0.06 0.07 0.13 0.13 CEO transition costs (1) — — 0.02 — Acquisition and integration related expenses (2) 0.03 — 0.03 — Stock-based compensation expense 0.10 0.07 0.18 0.13 Restructuring charges — 0.01 — 0.03 Impairment charges (3) 0.16 — 0.16 — IP litigation costs (4) 0.03 0.02 0.06 0.05 Other significant expenses, net (5) — 0.02 — 0.03 Rounding and impact of diluted shares in adjusted diluted shares (6) — (0.01 ) — — Adjusted diluted EPS (non-GAAP) $ 0.03 $ 0.03 $ 0.02 $ 0.01 Weighted average shares used in computation of adjusted diluted EPS: Diluted common shares (GAAP) 127,949 126,405 127,664 126,257 Dilutive effect of options, restricted stock, and converted shares (7)(8) — — — — Expand ____________________ Expand (1) For the three months ended June 30, 2025, CEO transition costs include executive retention costs. For the six months ended June 30, 2025, CEO transition costs include severance costs, executive retention costs, and executive search costs. There were no such costs for the three and six months ended June 30, 2024. (2) For the three and six months ended June 30, 2025, acquisition and integration related expenses include consulting and legal fees, severance costs, and employee retention costs. (3) For the three and six months ended June 30, 2025, impairment charges include losses from InVisionFirst®-Lung intangible asset impairment and inventory write-off, and impairment of disposal groups held for sale. There were no such costs for the three and six months ended June 30, 2024. (4) For the three and six months ended June 30, 2025 and June 30, 2024, IP litigation costs include legal fees. (5) For the three and six months ended June 30, 2024, other significant (income) expenses, net, includes site closure costs, severance costs, and fees related to non-recurring legal matters. There were no such costs for the three and six months ended June 30, 2025. (6) This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive or GAAP net (loss) income is positive and adjusted net (loss) income is negative, also compensates for the effects of additional diluted shares included or excluded in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes. (7) In those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. (8) In those periods in which GAAP net (loss) income is positive and adjusted net (loss) income is negative, this adjustment excludes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of common shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period. Expand Reconciliation of Non-GAAP Financial Guidance to Corresponding GAAP Measures (in thousands, except per share amounts) (unaudited) GAAP net loss in 2025 will be impacted by certain charges, including: (i) expense related to the amortization of intangible assets, (ii) stock-based compensation, and (iii) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net loss per share; however, they have been removed from adjusted net loss and adjusted diluted net loss per share The following table reconciles the Company's 2025 outlook for net loss and EPS to the corresponding non-GAAP measures of adjusted net loss, adjusted EBITDA, and adjusted diluted EPS: ____________________ Expand (1) This adjustment is for rounding and, in those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, also compensates for the effects of additional diluted shares included in adjusted diluted shares outstanding for the treasury stock impact of outstanding stock options and restricted stock and the if-converted impact of convertible notes. (2) For those periods in which GAAP net (loss) income is negative and adjusted net (loss) income is positive, this adjustment includes any options or restricted stock that would be outstanding as dilutive instruments using the treasury stock method and the weighted average number of shares that would be outstanding if the convertible notes were converted into common stock on the original issue date based on the number of days such shares would have been outstanding in the reporting period, until the effect of these adjustments are anti-dilutive. Expand Supplemental Information Clinical Tests Performed and Revenue (unaudited) ____________________ Expand (1) Excludes tests and revenue related to Pathline and non-clinical activity. (2) Excludes tests and revenue related to non-clinical activity. Expand
Time Business News
6 days ago
- Science
- Time Business News
NGS Gains Ground in Healthcare Amid Data Analysis Hurdles
Next-generation sequencing (NGS) is a massively parallel sequencing technology that can establish the order of nucleotides in a whole genome with scalability, ultra-high throughput, and rapid scale. DNA pre-sequencing is key to the whole sequencing process since it involves readying the sample for the next sequencing step. NGS is being used more and more in clinical lab work, testing, and illness diagnosis in healthcare all over the world. The lack of adaptable computer tools is a key factor limiting how quickly we can analyze and understand NGS data. People in the industry are working together to combine resources. The aim is to extract useful information from big, complex databases for medical treatments. Key Growth Drivers and Opportunities Increased Genome Mapping Programs: Genome mapping is the process of assigning genes to specific regions of chromosomes and determining the relative distances between genes. Genome mapping is driven by programs designed to obtain high-throughput data and helps us understand genetic disorders, evolutionary relationships, and how traits are inherited. Advances in sequencing tech have made genome mapping rapid, more precise, and cost effective. Increased Applications of Next Generation Sequencing: Labs can sequence whole genomes fast using Next-Generation Sequencing. Deep sequencing of target areas is a good idea. To study gene expression, measure mRNAs, or use RNA sequencing (RNA-Seq) to find new RNA variations and splicing sites. This method helps with thorough transcriptome profiling across different tissues, conditions, or health problems. It also helps find biomarkers and regulatory elements that change gene expression. RNA-Seq also gives info on post-transcriptional changes and non-coding RNAs. Challenges Next-generation sequencing demands qualified workers. So, large-scale testing isn't viable because it calls for great precision and skill. Data analysis complexity also means a need for trained bioinformaticians. Also, keeping protocols and quality consistent keeps being hard across labs. These limits may slow the spread of NGS in clinics and studies. Innovation and Expansion QIAseq Kit Cuts NGS Library Prep to 30 Minutes In July 2023, the launch of the QIAseq Normalizer Kits that give researchers a fast, convenient and cost-effective method to pool different DNA libraries for best-quality results from next-generation sequencing (NGS) runs. The QIAseq Normalizer Kit speeds up equalizing DNA concentrations across NGS libraries – so-called normalization – to 30 minutes from several hours by ending the need for quantifying DNA libraries using time-intensive and expensive procedures. It is high-throughput with an optimized protocol for parallel normalization of 96 samples, automation-friendly, and works without hazardous chemicals. Telesis Bio Ships First Automated NGS Plasmid Prep Kit In May 2023, Telesis Bio announced the first commercial shipment of its BioXp NGS Library Prep kit for plasmid sequencing. Leveraging this new automation capability of the BioXp platform is expected to enable researchers in high-throughput discovery workflows to reduce hands-on time, cost, and steps of NGS Library Preparation, both accelerating their time to answer and reducing barriers to access to Next-Generation Sequencing. This kit simplifies complicated procedures into an easy, automated process. This change allows for quicker and more scalable genomic studies in synthetic biology and molecular diagnostics. Inventive Sparks, Expanding Markets The key players operating the next-generation sequencing (NGS) market include Thermo Fischer Inc., Hoffmann-La Roche Ltd., among others. Global businesses are collaborating to make NGS data analysis and interpretation simpler. They want to find helpful information in complicated genomic data for better medical treatments. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
